Phase II pharmacokinetics of oral SM-88 in heavily pretreated advanced pancreatic ductal adenocarcinoma (PC).

Marcus Smith Noel; Martin Fernandez-Zapico; Gerald H. Sokol; Giuseppe Del Priore

doi:10.1200/JCO.2019.37.4_SUPPL.277

Phase II pharmacokinetics of oral SM-88 in heavily pretreated advanced pancreatic ductal adenocarcinoma (PC).

Marcus Smith Noel
, Martin Fernandez-Zapico
, Gerald H. Sokol
, Giuseppe Del Priore

Strong Memorial Hospital
Mayo Clinic
Florida Cancer Institute New Hope, Hudson, FL;
Tyme Technology, Inc., New York, NY;

Research output: Contribution to journal › Article › peer-review

Original language	American English
Journal	Journal of Clinical Oncology
Volume	37
DOIs	https://doi.org/10.1200/JCO.2019.37.4_SUPPL.277
State	Published - Jan 29 2019
Externally published	Yes

Disciplines

Medicine and Health Sciences
Oncology

Access to Document

10.1200/JCO.2019.37.4_SUPPL.277License: Unspecified

Cite this

@article{f879c801cc90426596b6b4e90b9d7aae,

title = "Phase II pharmacokinetics of oral SM-88 in heavily pretreated advanced pancreatic ductal adenocarcinoma (PC).",

author = "Noel, \{Marcus Smith\} and Martin Fernandez-Zapico and Sokol, \{Gerald H.\} and \{Del Priore\}, Giuseppe",

note = "277 Background: SM88 is an oral tyrosine isomer (TI) and repurposed drugs (CYP3a4 inducer, mTOR inhibitor, oxidative stress catalyst). This regimen has reported no drug related grade 3, 4 or 5 adverse events (JCO 2013 31: e22095) and potential clinical activity in PC (JCO 2018 36: TPS 4156).",

year = "2019",

month = jan,

day = "29",

doi = "10.1200/JCO.2019.37.4\_SUPPL.277",

language = "American English",

volume = "37",

journal = "Journal of Clinical Oncology",

}

TY - JOUR

T1 - Phase II pharmacokinetics of oral SM-88 in heavily pretreated advanced pancreatic ductal adenocarcinoma (PC).

AU - Noel, Marcus Smith

AU - Fernandez-Zapico, Martin

AU - Sokol, Gerald H.

AU - Del Priore, Giuseppe

N1 - 277 Background: SM88 is an oral tyrosine isomer (TI) and repurposed drugs (CYP3a4 inducer, mTOR inhibitor, oxidative stress catalyst). This regimen has reported no drug related grade 3, 4 or 5 adverse events (JCO 2013 31: e22095) and potential clinical activity in PC (JCO 2018 36: TPS 4156).

PY - 2019/1/29

Y1 - 2019/1/29

UR - https://ascopubs.org/doi/abs/10.1200/JCO.2019.37.4_suppl.277

U2 - 10.1200/JCO.2019.37.4_SUPPL.277

DO - 10.1200/JCO.2019.37.4_SUPPL.277

M3 - Article

VL - 37

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

ER -

Phase II pharmacokinetics of oral SM-88 in heavily pretreated advanced pancreatic ductal adenocarcinoma (PC).

Disciplines

Access to Document

Other files and links

Cite this